Segall Bryant & Hamill LLC Makes New Investment in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Segall Bryant & Hamill LLC bought a new stake in Dr. Reddy’s Laboratories Limited (NYSE:RDY) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 45,100 shares of the company’s stock, valued at approximately $712,000.

Other institutional investors also recently modified their holdings of the company. Robeco Institutional Asset Management B.V. boosted its stake in Dr. Reddy’s Laboratories by 453.8% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company’s stock valued at $180,620,000 after acquiring an additional 9,373,412 shares during the last quarter. Aikya Investment Management Ltd lifted its stake in shares of Dr. Reddy’s Laboratories by 416.1% in the 4th quarter. Aikya Investment Management Ltd now owns 5,610,503 shares of the company’s stock valued at $88,590,000 after purchasing an additional 4,523,303 shares during the period. Vanguard Group Inc. boosted its position in shares of Dr. Reddy’s Laboratories by 397.2% in the 4th quarter. Vanguard Group Inc. now owns 4,896,185 shares of the company’s stock worth $77,311,000 after purchasing an additional 3,911,404 shares during the last quarter. Fisher Asset Management LLC grew its stake in shares of Dr. Reddy’s Laboratories by 402.5% during the fourth quarter. Fisher Asset Management LLC now owns 2,468,722 shares of the company’s stock worth $38,981,000 after purchasing an additional 1,977,419 shares during the period. Finally, American Century Companies Inc. lifted its stake in Dr. Reddy’s Laboratories by 418.1% in the fourth quarter. American Century Companies Inc. now owns 862,365 shares of the company’s stock valued at $13,617,000 after buying an additional 695,932 shares during the period. Institutional investors and hedge funds own 3.85% of the company’s stock.

Dr. Reddy’s Laboratories Stock Performance

Shares of Dr. Reddy’s Laboratories stock opened at $13.20 on Friday. The stock’s fifty day simple moving average is $13.48 and its 200 day simple moving average is $14.61. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $11.01 billion, a PE ratio of 21.01 and a beta of 0.48. Dr. Reddy’s Laboratories Limited has a 12 month low of $12.50 and a 12 month high of $16.89.

Dr. Reddy’s Laboratories (NYSE:RDY) last released its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, topping analysts’ consensus estimates of $0.19 by $0.01. Dr. Reddy’s Laboratories had a return on equity of 17.87% and a net margin of 17.25%. On average, research analysts predict that Dr. Reddy’s Laboratories Limited will post 0.8 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on RDY shares. Nomura lowered Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research report on Thursday, December 19th. StockNews.com cut shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a report on Friday, December 6th.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.